9.9 Conclusions
Tables
Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |